Atrial Fibrillation (AF) Clinical Trials in Dallas, Texas

3 studies are recruiting for atrial fibrillation (af) in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

   This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Southwest Family Medicine Associates, Dallas, Texas

   Locations

   35 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07430956 on ClinicalTrials.gov

2. Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

   Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single p…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Texas Cardiac Arrhythmia Research Foundation, Dallas, Texas

   Locations

   30 in total

   Run by

   Medtronic Cardiac Ablation Solutions

   See if you can join NCT07298473 on ClinicalTrials.gov

3. Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

   A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

   Stage

   Phase 3

   Ages

   65 and older

   Site

   Anthos Investigative Site 9943, Dallas, Texas

   Locations

   789 in total

   Run by

   Anthos Therapeutics, Inc.

   See if you can join NCT05712200 on ClinicalTrials.gov